Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Daiichi Sankyo, Ranbaxy To Start Joint Marketing In Mexico, Romania

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Dust from their merger settled, Daiichi Sankyo and generics manufacturing Indian subsidiary Ranbaxy are flexing their muscles, readying to start marketing brand and generic pharmaceuticals in Mexico and launching the postmenopausal osteoporosis drug Evista in Romania
Advertisement

Related Content

Daiichi Sankyo, Ranbaxy To Launch Olmesartan In Six African Countries
Daiichi Sankyo, Ranbaxy To Launch Olmesartan In Six African Countries
Japanese Pharma Expects New Deal Model For Next 20 Years - New York Pharma Forum
Japanese Pharma Expects New Deal Model For Next 20 Years - New York Pharma Forum
As India's Exports Take Off, Building Brand India Will Be Key Focus, Says Government
Daiichi Sankyo Expands MorphoSys Alliance To Include Antibodies For Infectious Disease
Japanese Pharmas Investing Heavily in Emerging Markets - BioJapan Conference
Japanese Pharmas Investing Heavily in Emerging Markets - BioJapan Conference
Indian Tribunal Back Zenotech, Daiichi Sankyo's Struggle On Open Offer Price Continues
Indian Tribunal Back Zenotech, Daiichi Sankyo's Struggle On Open Offer Price Continues
Advertisement
UsernamePublicRestriction

Register

SC070245

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel